ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Targeting the Constitutively Active PI3K/Akt/mTOR Signaling Pathway in Epstein-Barr Virus B Cell Lymphomas.

A. Sang, G. Ivison, C. Esquivel, S. Krams, O. Martinez.

Division of Abdominal Transplantation, Stanford School of Medicine, Stanford, CA.

Meeting: 2016 American Transplant Congress

Abstract number: 457

Keywords: Epstein-Barr virus (EBV), Graft survival, Immunosuppression, Post-transplant lymphoproliferative disorder (PTLD)

Session Information

Date: Tuesday, June 14, 2016

Session Name: Concurrent Session: PTLD and Malignancies

Session Time: 2:30pm-4:00pm

 Presentation Time: 3:06pm-3:18pm

Location: Room 206

Related Abstracts
  • PI3Kδ Inhibition Augments the Efficacy of mTOR Inhibitor Rapamycin on the Proliferation of Epstein-Barr Virus (EBV)+ B Cell Lymphomas
  • Epstein Barr Virus Modulates Host Cell MicroRNA-194 to Promote IL-10 Production in B Cell Lymphomas

Epstein-Barr virus (EBV) B cell lymphomas in post-transplant lymphoproliferative disorder (PTLD) is a major problem in organ transplantation. Reduction of immunosuppression sometimes result in tumor regression but also puts the graft at risk for rejection. Therefore, treatments that combine anti-tumor and anti-rejection properties would be of great importance to PTLD patients.

Previous studies have shown that multiple cellular signal transduction pathways, including the PI3K/Akt/mTOR pathway, are dysregulated in EBV+ B cell lymphomas, and that inhibiting mTOR with rapamycin results in partial inhibition of proliferation. We hypothesized that targeting molecules upstream of mTOR would inhibit EBV+ B cell lymphoma proliferation. Moreover, blockade of this pathway may prolong graft survival, since this pathway is also known to be activated downstream of the T cell receptor.

Phosphorylation of the PI3K/Akt/mTOR pathway was determined by protein array on cellular lysates from EBV+ B cell lymphoma lines from patients (n=5) with PTLD. The effect of small molecular inhibitors of the pathway on cellular proliferation was also determined. Finally, the effect of these inhibitors on graft survival was assessed using a fully MHC mismatched heterotopic mouse heart transplant model (Balb/c to C57Bl/6).

EBV+ B lymphoma cell lines showed hyperactivation of multiple nodes along the PI3K/Akt/mTOR pathway, including mTOR, 4E-BP1, S6K, and GSK3α/β, compared to normal human B cells and EBV- Burkitt's lymphoma cells. Several upstream signals such as PDK3 and Akt were also constitutively phosphorylated, supporting their role as potential therapeutic targets. Hierarchical clustering distinguished the EBV+ B cell lines from EBV- B cells. Inhibiting upstream PI3K with the small molecule inhibitor CAL101 resulted in a dose-dependent decrease in proliferation (x=51.6±6.6%, range 39.8-62.6%) of the EBV+ B cell lymphoma lines (n=3). Likewise, inhibition of Akt with MK2206 also decreased proliferation (x=52.1±3.5%, range 46.5-58.5%) in a dose-dependent manner.

Finally, in vivo treatment with either CAL-101 or MK2206 prolonged allograft survival from 8.75 days (control) to 21.2 (SEM ±4.48, n=6) and 20.5 (±4.31, n=6) days, respectively. Thus, inhibition of signaling nodes upstream of mTOR, such as PI3K and Akt, demonstrates anti-tumor properties, and the attractiveness of these regimens clinically is complemented by their immunosuppressive effects.

CITATION INFORMATION: Sang A, Ivison G, Esquivel C, Krams S, Martinez O. Targeting the Constitutively Active PI3K/Akt/mTOR Signaling Pathway in Epstein-Barr Virus B Cell Lymphomas. Am J Transplant. 2016;16 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Sang A, Ivison G, Esquivel C, Krams S, Martinez O. Targeting the Constitutively Active PI3K/Akt/mTOR Signaling Pathway in Epstein-Barr Virus B Cell Lymphomas. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/targeting-the-constitutively-active-pi3kaktmtor-signaling-pathway-in-epstein-barr-virus-b-cell-lymphomas/. Accessed February 27, 2021.

« Back to 2016 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
      • Penis Transplantation: First U.S. Experience.
      • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
      • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
      • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
      • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

      Visit Our Partner Sites

      American Transplant Congress (ATC)

      Visit the official site for the American Transplant Congress »

      American Journal of Transplantation

      The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

      American Society of Transplantation (AST)

      An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

      American Society of Transplant Surgeons (ASTS)

      The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

      Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

      Privacy Policy

      loading Cancel
      Post was not sent - check your email addresses!
      Email check failed, please try again
      Sorry, your blog cannot share posts by email.
      This site uses cookies: Find out more.